Acute Myeloid Leukemia

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

I recently was invited to give a presentation about genomic alterations in AML at the 2024 ASTCT Clinical Education Conference for advanced practice providers, nurses and fellows.

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined time to treatment initiation in patients with acute myeloid leukemia.

In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined the use of a new class of menin inhibitors on two different types of mutated acute myeloid leukemia.

In this video, Daniel DeAngelo, MD, PhD, discusses a study presented at ASH Annual Meeting that examined the KOMET-007 study into the use of menin inhibitors in patients with acute myeloid leukemia.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting.

In this video, Moath Albliwi, MD, discusses the results of a study he co-presented at ASH Annual Meeting and Exposition that examined treatment of elderly patients with acute myeloid leukemia.

SAN DIEGO — Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Successfully addressing financial toxicity for people with blood cancer will require substantial efforts from a variety of stakeholders, according to a speaker at ASH Annual Meeting and Exposition.